C-X-C motif chemokine receptor 2, Coagulation factor II thrombin receptor, Matrix metalloproteinase-1, Matrix metalloproteinase-2, Matrix metalloproteinase-3, Vascular cell adhesion molecule 1

The target name provided is a composite list of six distinct proteins: C-X-C motif chemokine receptor 2 (CXCR2), Coagulation factor II thrombin receptor (F2R/PAR1), Matrix metalloproteinase-1 (MMP1), Matrix metalloproteinase-2 (MMP2), Matrix metalloproteinase-3 (MMP3), and Vascular cell adhesion molecule 1 (VCAM-1). CXCR2 is a G protein-coupled receptor (GPCR) primarily responsible for neutrophil chemotaxis and activation in response to IL-8 (Murphy & Tiffany, 1991 [1]). F2R, also known as Protease-activated receptor 1 (PAR1), is a GPCR that mediates the cellular effects of thrombin, playing a critical role in platelet aggregation and vascular signaling (Vu et al., 1991 [2]). MMP1, MMP2, and MMP3 are members of the matrix metalloproteinase family, which are zinc-dependent enzymes that degrade various components of the extracellular matrix, facilitating tissue remodeling and cell migration (Nagase et al., 2006 [3]). VCAM-1 is a cell surface sialoglycoprotein that mediates the adhesion of leukocytes to the vascular endothelium, a key step in the inflammatory response (Osborn et al., 1989 [4]). Collectively, these proteins are central to the pathophysiology of atherosclerosis, chronic inflammation, and tumor metastasis, where they coordinate leukocyte recruitment and matrix degradation (Libby, 2002 [5]). While individual drugs like Vorapaxar (targeting F2R) and Navarixin (targeting CXCR2) have been developed, this specific combination of proteins is typically analyzed as a panel of inflammatory markers rather than a single therapeutic target (StatPearls, 2023 [6]).

Other names

CXCR2F2RMMP1MMP2MMP3VCAM-1Protease-activated receptor 1 (PAR1)Interstitial collagenase72 kDa type IV collagenaseStromelysin-1Vascular cell adhesion protein 1CD106

This target set involves multiple mechanisms: antagonism of the CXCR2 and F2R (PAR1) G protein-coupled receptors to inhibit chemotaxis and thrombin signaling; inhibition of the proteolytic activity of MMP1, MMP2, and MMP3 to prevent extracellular matrix degradation; and the blockade of VCAM-1 to prevent leukocyte-endothelial adhesion.